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Background: Hemolytic uremic syndrome (HUS) leading to acute kidney failure, is a condition linked to the
production of primarily Shiga toxin 2 (Stx2) by some E. coli serotypes. We have previously shown that Stx2 A
subunit-specific human monoclonal antibody (HuMAb) 5C12, and B subunit-specific HuMAb 5H8 inhibit cultured
cell death, and protect mice and piglets from fatal Stx2-intoxication. We have also shown that 5H8 blocks binding
of Stx2 to its cell-surface receptor globotriaosyl ceramide (Gb3), whereas Stx2 when complexed with 5C12 binds Gb3
with higher affinity than Stx2. The mechanism by which 5C12 neutralizes Stx2 in vitro involves trapping of Stx2 in
the recycling endosomes and releasing it into the extracellular environment. Because of the clinical implications
associated with the formation of Stx2/antibody complexes and the potential for trapping and clearance through a
severely damaged kidney associated with HUS, we investigated the likely site(s) of Stx2/antibody localization and
clearance in intoxicated mice treated with antibody or placebo.
Results: Mice were injected with radiolabeled Stx2 (125I-Stx2) 4 hours after administration of 5C12, 5H8, or
phosphate buffered saline (PBS) and the sites of localization of labeled Stx2, were investigated 3, 24 and 48 hours
later. The liver recorded statistically much higher concentrations of labeled Stx2 for groups receiving 5C12 and 5H8
antibodies after 3, 24 and 48 hours, as compared with the PBS group. In contrast, highest levels of labeled Stx2
were detected in the kidneys of the PBS group at all 3 sampling times. Mice receiving either of the two HuMAbs
were fully protected against the lethal effect of Stx2, as compared with the fatal outcome of the control group.
Conclusions: The results suggest that HuMAbs 5C12 and 5H8 promoted hepatic accumulation and presumably
clearance of toxin/antibody complexes, significantly diverting Stx2 localization in the kidneys, the target of Stx2 and
the cause of HUS. This is in contrast to the fatal outcome of the control group receiving PBS. The results also
confirm earlier observations that both HuMAbs are highly and equally protective against Stx2 intoxication in mice.
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Infection with Shiga toxin (Stx)-producing Escherichia coli
(STEC) is the most significant cause of hemolytic uremic
syndrome (HUS), the leading cause of acute renal failure in
children [1-4]. Of the two antigenically distinct toxins, Stx1
and Stx2, Stx2 is more firmly linked with the development
of HUS. Stx1 and Stx2 are similar in basic structure [5],
binding specificity [5] and mode of action. Epidemiologic
studies show that Stx2-producing strains are more fre-
quently associated with HUS than strains that produce both
Stx1 and Stx2; while Stx1 alone has rarely been associated
with HUS [6-8].
Stx1 and Stx2 consist of an A-subunit monomer and a
B-subunit pentamer [5,9,10]. The pentameric B subunit
binds to its cell surface receptor globotriaosyl ceramide
(Gb3; Galα1-4Galβ1-4glucosyl ceramide) [11,12]. Inter-
nalized Stx follows retrograde transport to the trans-
Golgi network and subsequently to the endoplasmic
reticulum and cytosol [13,14]. During this trafficking,
the A subunit is nicked by the membrane-bound furin
protease, generating a catalytically active N-terminal
A1 fragment and a C-terminal A2 fragment; both frag-
ments remain linked by a disulfide bond [13,15]. The
disulfide bond is subsequently reduced, and the active
A1 component is released. The released A1 fragment has
N-glycosidase catalytic activity and it removes a specific
adenine base from the 28S rRNA of the 60S ribosomal
subunit [16,17]. Because this adenine base is on a loop of
rRNA that is important for elongation factor binding,
Stx is able to shut down the protein synthesis and cause
cell death.
We have produced human monoclonal antibodies
(HuMAbs) against Stx1 and Stx2, and evaluated them in
animal models for their efficacy against systemic chal-
lenge with the toxins [18,19]. We selected 5C12, a Stx2
A subunit-specific HuMAb, based on its superior efficacy
in protecting mice against lethal challenge with Stx2 and
Stx2 variants [20] for preclinical evaluation in the piglet
diarrhea model challenged orally with STEC. This anti-
body protected piglets against Stx2-induced fatal neuro-
logical symptoms, even when administered well after the
onset of diarrhea following oral STEC challenge (48
hours post-challenge) [21]. In this model, diarrheal
symptoms precede systemic complications associated
with Stx2 uptake from the gut, as is observed in children.
Similarly, Stx2 B subunit-specific HuMAb 5 H8 also pro-
tects piglets [18] and mice against Stx2 intoxication
[18,21].
While these HuMAbs completely protect healthy piglets
and mice from Stx2-mediated death, there remains a con-
cern among nephrologists for the potential formation of im-
mune Stx2/antibody complexes in a severely damaged
kidney of patients with HUS. In the mouse model, the kid-
neys are the major target organ of Stx2-intoxication. In thismodel, Stx2 causes apoptosis of medullary and cortical
tubular cells in the kidneys, and leads to renal failure due to
the loss of functioning collecting ducts [22]. In the present
experiments we investigated the likely site of Stx2/antibody
localization and clearance using the mouse model of sys-




Stx2, purified from E. coli C600W as described previ-
ously [23], was obtained from Phoenix Laboratory
(Tufts University-NEMC Microbial Products & Ser-
vices Facility). The toxin was dissolved at 500 μg/ml
in phosphate buffered saline (PBS), aliquoted and
stored at −20°C.
Stx2-specific HuMAbs
Production of Stx2A-specific 5C12 and Stx2B-specific 5H8
HuMAbs have been described elsewhere [18,21]. These anti-
bodies were purified by protein A affinity chromatography,
dialyzed against PBS, quantified by UV spectrophotometry
(ND-1000 Spectrophotometer, Nanodrop), aliquoted, and
stored at −20°C.
Iodination of Stx2
Purified Stx2 was iodinated by a modification of the
chloramine T method [24,25]. Briefly, one millicurie of
carrier-free Na125I (PerkinElmer, Billerica, MA) was
added to 20 to 30 μg of Stx2 in 100 μl of PBS. Then,
20 μl of chloramine T (2.5 mg/ml in PBS; GFS Chemi-
cals, Columbus, OH) was added, and incubated for 20
seconds. The iodination was terminated by adding 20 μl
of sodium metabisulfite (5 mg/ml in distilled water;
Sigma, St. Louis, MO). Ten μl of potassium iodide
(20 mg/ml in PBS; Sigma) was subsequently added to
scavenge the free iodine. The iodinated Stx2 (125I-Stx2)
was separated from free 125I by filtration through a poly-
acrylamide column (D-saltTM columns; Pierce, Rockford,
IL).
Biodistribution of 125I-Stx2, and 125I-Stx2/HuMAb
complexes
The mouse toxicity model [21] was used to study biodistri-
bution of 125I-Stx2, and 125I-Stx2/HuMAb complexes.
Four-week-old female C57BL/6 mice weighing 18–22 g
(Charles River Laboratories) were injected intraperitone-
ally (IP) with PBS or 30 μg/mouse of a Stx2-specific
HuMAb (5C12 or 5H8). After 4 hr, mice were adminis-
tered intravenously (IV) with 100 ng/mouse (in 100 μl of
PBS) of 125I-Stx2 as a single bolus dose. The 125I-Stx2 dose
of 100 ng/mouse is 4 times the LD100 dose [21]. An iso-
type control was not included in the current experiments
as we have consistently found no difference between
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antibody does not interact with the toxin and mice
die within 3 days of either PBS or isotype control
antibody administration [21]. Similarly, piglets also
succumb to Stx2-mediated systemic complication fol-
lowing either PBS or isotype control antibody admin-
istration [21]. A group of 3 mice from each
treatment group (5C12 or 5H8 or PBS) was eutha-
nized at 3 h, 1 and 2 days post-125I-Stx2 injection.
Blood was collected from these mice before euthan-
asia, and tissues and urine were collected after eu-
thanasia. The fluids and tissues were analyzed for
radioactivity by a gamma counter (1470 Wallac wiz-
ard, Global Medical Instrumentation, Inc., Ramsey,
MN). A group of 5 mice injected IV with 100 ng of
125I-BSA was used as a control to the radiolabeled
toxin injected group.
Stx2 was labeled again with 125I and the experiment
repeated once to obtain 6 mice per treatment group. The
data were presented as a percentage of injected dose of
radioactive toxin (125I-Stx2) per gram (% ID/g) of an
organ tissue, or per ml (% ID/ml) of a fluid. The% ID/g
or% ID/ml was calculated by the formula: (counts per



















lBiological activity of the radiolabeled Stx2
The mouse toxicity model was also used to ensure that
radiolabeled Stx2 was biologically active and that Stx2-
specific HuMAbs neutralized the toxin activity. Briefly,
30 μg/mouse of a Stx2-specific HuMAb, or PBS, was
injected IP 4 hr prior to IV administration of 100 ng
125I-Stx2/mouse. Mice were observed 3 or more times
daily for clinical signs and survival until 11 day post-
toxin administration.
All animal studies described in the above 2 sections
were performed in accordance with the guidelines of the















Figure 1 (A): 12% SDS PAGE gel stained with Coomassie blue
shows Stx2 preparation was pure as it contained only A and B
subunits of Stx2 (lane 2); the molecular weight markers (in
thousands) were in lane 1. (B): Survival of mice given
intraperitoneally PBS or 30 μg of HuMAbs 5C12 or 5H8 followed 4
hours later with intravenous administration of 100 ng of 125I-Stx2.
Mice in PBS group died between 57–64 h or 2.3-2.6 days after 125I-
Stx2 injection. Both 5C12 and 5H8 protected 100% of mice until the
end of the experiment (264 h or 11 days).Statistical analysis
For statistical analysis of total radioactivity remaining in
the body following 3 h, 1 and 2 days of 125I-Stx2 injec-
tion in different treatment groups, the pair wise com-
parison was done using Student t-test and Wilcoxon
rank test. For statistical analysis of radioactivity in each
organ at a particular time point (3 h, 1 day or 2 days
post-125I-Stx2 injection), nonparametric Kruskal-Wallis
and Wilcoxon rank tests were performed to evaluate sig-
nificant differences among the four treatment groups.
The analyses were performed using statistical software
(SAS 9.2). Resulting p-values of less than 0.05 were con-
sidered significant.Results
Biological activity of radiolabeled (125I-Stx2) and
neutralization of 125I-Stx2 by Stx2-specific HuMAbs
Purified Stx2 consisted of only A and B subunits
(Figure 1A). 125I-Stx2 was biologically active as none
of the mice survived 125I-Stx2 challenge in the PBS
group (Figure 1B). They either died or became se-
verely ill and were euthanized 57–64 h or 2.3-2.6 days
following toxin administration (Figure 1B). All Stx2-
specific HuMAbs neutralized the lethal biological ac-
tivity of 125I-Stx2 as all mice in HuMAb groups sur-
vived the 125I-Stx2 challenge until the end of the
experiment (264 h or 11 day post-toxin challenge)
(Figure 1B).
Distribution of 125I-Stx2, and 125I-Stx2/HuMAb complexes
in blood
In the control 125I-BSA group, 98% of 125I-BSA was
eliminated from the body, and most of the remaining 2%
125I-BSA was localized in urine and blood 1 day post-
125I-BSA administration (results not shown).
At 3 h post-125I-Stx2 administration, the toxin loca-
lized significantly more in blood of groups receiving
HuMAbs 5C12 or 5H8 than the PBS group (Figure 2).
However, the concentration of the toxin between the
HuMAb groups did not differ significantly at this time
point.
On days 1 and 2, the toxin localized significantly more
in blood of groups receiving HuMAbs 5C12 than the
PBS and 5H8 groups (Figure 2). The toxin concentration
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Figure 2 Distribution of 125I-Stx2 in body fluids following 3 h, 1 and 2 days of 125I-Stx2 injection. Mice were given intraperitoneally PBS or
30 μg of HuMAbs 5C12 or 5H8 followed 4 hours later with intravenous administration of 100 ng of 125I-Stx2. Distribution of 125I-Stx2 in body fluids
was determined following 3 h, day 1 and day 2 of 125I-Stx2 injection, and expressed as “% injected dose (ID)/ml fluid”. Bars with different letters (a
and b) within a body fluid at a particular sampling time point indicate differences are statistically significant (p< 0.05) among those treatment
groups. Bars with same letter within a body fluid at a particular sampling time point indicate differences are not statistically significant among
those treatment groups.
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blood in each group was: 5C12> 5H8> PBS (Figure 2).
Distribution of 125I-Stx2, and 125I-Stx2/HuMAb complexes
in urine
Excretion of radioactivity in urine did not differ signifi-
cantly between treatment groups at 3 h and 1 day after
125I-Stx2 administration (Figure 2). On day 2, the radio-
activity localized significantly more in the urine of
HuMAb groups than the PBS group (Figure 2).
Distribution of 125I-Stx2, and 125I-Stx2/HuMAb complexes
in tissues
At 3 h, the toxin concentration in the PBS group was
significantly different from both 5C12 and 5H8 antibody
treatment groups in only two organs, the kidneys and
the liver (Figure 3 and Table 1). In the cerebrum, the
toxin concentration in the 5H8 group was significantly
different from the PBS and 5C12 groups, and in the
stomach, the toxin concentration in the 5H8 group was
significantly different from the 5C12 group but not from
the PBS group (Figure 3). In the mesenteric lymph nodes
(MLN), the toxin concentration in the 5H8 group dif-
fered significantly from the PBS group but not from the
5C12 group (Figure 3). The toxin concentration in any of
the remaining organs did not differ significantly between
any treatment groups (Figure 3, Additional file 1: Table
S1). Based on the numerical mean radioactivity concen-
tration, highest concentrations were found in the kidneys
(41%), liver (23%) and liver (25%) of PBS, 5C12 and 5H8
groups, respectively (Figure 3 and Table 1). While the
toxin concentration in the kidneys was significantly
greater in the PBS group than the HuMAb groups, it didnot differ significantly among kidneys of the 5C12 and
5H8 groups. The toxin concentration in the liver was sig-
nificantly higher in the 5C12 and 5H8 groups than in the
PBS group but did not differ significantly between the
5C12 and 5H8 groups.
On day 1, the toxin concentration in the PBS group
again differed significantly from both 5C12 and 5H8
antibody treatment groups in only two organs, the kid-
neys and the liver (Figure 3 and Table 1). In the MLN,
the toxin concentration in the 5H8 group differed signifi-
cantly from the PBS and 5C12 groups (Figure 3), and in
the heart, the toxin concentration in the PBS group dif-
fered significantly from the 5C12 group but not from the
5H8 group (Additional file 1: Table S1). The toxin con-
centration in any of the remaining organs did not differ
significantly between any treatment groups (Figure 3,
Additional file 1: Table S1). Maximal levels of Stx2 loca-
lized in the kidneys of PBS (43%) group, in the kidneys
(11%) and liver (8%) of 5H8 group, and in the liver,
spleen and kidneys (~10%) of 5C12 group (Figure 3 and
Table 1). Liver was a major organ of toxin accumulation
in 5H8 and 5C12 groups but not in PBS (4%) group. The
toxin concentration in the kidneys of the PBS group was
significantly greater than in the kidneys of the 5C12 and
5H8 groups. The toxin concentration in the liver of the
PBS was significantly lower than that of the 5C12 and
5H8 groups. The toxin concentration in the liver and
kidneys did not differ significantly between the 5C12 and
5H8 groups.
On day 2, based on the numerical means, the kidneys
were the organ where maximum toxin accumulated in
the PBS (13%) group, whereas maximal levels of the










































































































































































Figure 3 Distribution of 125I-Stx2 in tissues following 3 h, 1 and 2 days of 125I-Stx2 injection. Mice were given intraperitoneally PBS or 30
μg of HuMAbs 5C12 or 5H8 followed 4 hours later with intravenous administration of 100 ng of 125I-Stx2. Distribution of 125I-Stx2 in body tissues
was determined following 3 h, day 1 and day 2 of 125I-Stx2 injection, and expressed as “% injected dose (ID)/g tissue”. Bars with different letters
(a-c) within a tissue indicate differences are statistically significant (p< 0.05) among those treatment groups. Bars with same letter within a tissue
indicate differences are not statistically significant among those treatment groups.
Sheoran et al. BMC Immunology 2012, 13:27 Page 5 of 8
http://www.biomedcentral.com/1471-2172/13/27
Table 1 Distribution of 125I-Stx2 in the kidney and liver following 3 h, 1 day and 2 days of 125I-Stx2 injection1
Sampling time Tissue PBS 5C12 5H8
3 h Kidney 41±24.1a 11±3.4b 8±2.6b
Liver 5±0.4a 23±4.8b 25±4.9b
Day 1 Kidney 43±29.1a 9±4.0 b 11±19.1b
Liver 4±1.9a 10±1.8b 8±1.9b
Day 2 Kidney 13±1.7a 4±1.2b 1±0.c
Liver 1±0.1a 3±0.6b 2±0.1c
1Distribution of 125I-Stx2 in the kidney and the liver following 3 h, 1 day and 2 days of 125I-Stx2 injection. Mice were given intraperitoneally PBS or 30 μg of
HuMAbs 5C12 or 5H8 followed 4 hours later with intravenous administration of 100 ng of 125I-Stx2. Distribution of 125I-Stx2 in the kidney and the liver was
determined following 3 h, 1 day and 2 days of 125I-Stx2 injection, and expressed as “% injected dose (ID)/g tissue”.
a-c Values with different letters (superscripts ‘a’, ‘b’ and ‘c’) within a tissue indicate differences are statistically significant (p< 0.05) among those treatment groups.
Values with same letter superscript within a tissue indicate differences are not statistically significant among those treatment groups.
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spleen (3-4%) (Figure 3 and Table 1). Significantly more
toxin localized in the livers of the 5C12 and 5H8 groups
than the liver of PBS group. The toxin was barely detect-
able in cerebrum and cerebellum (Figure 3), and other
organs (Additional file 1: Table S1).
Discussion
The purpose of this investigation was to establish the site
(s) of Stx2 accumulation in the intoxicated host, and
whether administration of highly protective antibodies
impacts this outcome. In addition, the site of accumulation
of Stx2/antibody complexes in patients with HUS is of par-
ticular concern to nephrologists, should the site be the kid-
neys leading to further renal dysfunction. The results of
the present study suggest that HuMAbs 5C12 and 5H8
facilitated hepatic clearance of Stx2 as maximal levels of
radioactivity in these groups were present in the liver at
3 h after 125I-Stx2 administration. The liver was also a
major organ of radioactivity accumulation in these 2
groups at day 1 and day 2 sampling times, largely sparing
the kidney. In contrast, kidneys were the major target
organ of 125I-Stx2 accumulation in the PBS group at all 3
sampling times, indicating that rapid hepatic elimination
of Stx2 did not occur in this group. Other studies have
previously shown that soluble immune complexes are
cleared primarily by the liver through uptake into Kupffer
cells [26-28].
The results of the present study show that accumulation
of Stx2 in the kidneys is significantly blocked by the
HuMAbs 5C12 and 5H8 as radioactivity accumulated in
the kidneys of these two groups at much lower levels than
the kidneys of the PBS group. As all mice in the 5C12 and
5H8 groups did not show any clinical signs of Stx2-intoxi-
cation and survived, the renal presence of Stx2 in these
mice appear to have had minimal clinical impact. In con-
trast, all mice in the PBS group succumbed to Stx2-
intoxication, and toxin presence in the kidneys of this
group may have contributed to their deaths. Stx2 in the
kidneys of mice is toxic and causes apoptosis of medullaryand cortical tubular cells, and renal failure due to the loss
of functioning collecting ducts [22]. These results suggest
that Stx2/5C12 or Stx2/5H8 complexes are less likely to
accumulate in the kidneys in patients with HUS, and less
likely to exacerbate the condition further.
Gb3 expression on neuronal cells in mouse central
nervous system and its binding with Stx2 has recently
been shown [29], which also explains earlier observations
of Stx2 localization in the spinal cord [30]. In the present
study, significantly more toxin was measured in the cere-
brum but not cerebellum of the PBS and 5C12 groups
than in the 5H8 group at the 3 h sampling time. This
suggests that toxin can bind to the cerebrum but not the
cerebellum, and that 5H8 but not 5C12 can block this
binding. Significant differences in toxin accumulation in
cerebrum or cerebellum did not occur on day 1 or day 2
in any of the groups. Note however, that in the present
study, cerebral toxin accumulation in PBS and 5C12
groups was much less than the accumulation of toxin in
the kidney, a well known target of Stx2. The spinal cord
was not included in the present study.
The stomach was one of the major organs of radio-
activity accumulation (especially at 3 h sampling time) in
all treatment groups. The stomach has previously been
shown to accumulate radioactivity in mice injected with
radiolabeled Stx2 [30]. Presumably, sequestration of the
released radioiodide in the stomach may have occurred
due to the dehalogenation effect [31].
Rutjes et al. [30] reported that the highest concentra-
tions of Stx2 localized in the nasal turbinates followed by
the lungs and kidneys. Stx2-specific antibodies were not
used in that study [30]. The lungs, but not the nasal tur-
binates were included in the present study, and with
regards to toxin concentration, they were the fourth
highest in the PBS and 5H8 groups, and the sixth highest
in 5C12 group at 3 h sampling time (Figure 3, Additional
file 1: Table S1). As the previous [30] and the present
studies used radioiodinated Stx2 and the IV route of
toxin administration, the discrepancy between the two
investigations may be related to sampling time after
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the strain of mouse used (Balb/c vs. C57BL/6 in our
study). Nevertheless, the kidney was a major target organ
for Stx2 in both studies [30]. Stx2 is known to have a
propensity for lymphoid cells [32-34] as is shown by
binding of the toxin within MLN in the present study.
Conclusions
The results of the present study suggest that the inter-
action of Stx2 with HuMAbs 5C12 and 5H8 inhibited ac-
cumulation of the toxin in the kidney, the major target
organ of Stx2-intoxication, and lead instead to rapid ac-
cumulation of Stx2 in the liver, an organ known to clear
soluble immune complexes in vivo [26-28].
Additional file
Additional file 1: Table S1. Distribution of 125I-Stx2 in body fluids and
tissues following 3 h, 1 day and 2 days of 125I-Stx2 injection.1
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